SEATTLE — Patients with age-related macular degeneration in a veteran population experienced an increase in inactive disease after treatment with faricimab, according to a poster presented here.
“Faricimab, or Vabysmo (Genentech), was effective at creating inactive disease to a statistically significant degree in age-related macular degeneration patients in a national cohort study of the Veterans Affairs,” Daniel Fraser told Healio at the Association for Research in Vision and Ophthalmology meeting.
Fraser and colleagues investigated the short-term efficacy of faricimab on